
|Videos|February 9, 2021
TAILORx Trial
Author(s)Cancer Network Staff
Advertisement
A review of the TAILORx trial using the Oncotype DX assay to inform decisions in the adjuvant setting for treatment of HR+, HER2- breast cancer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
2
Sevabertinib Monotherapy Elicits Durable Responses in HER2-Mutant NSCLC
3
Episode 16: Anticipated ESMO 2025 Data That May Change GU Oncology
4
Zongertinib Maintains Efficacy Benefit in First-line HER2-Mutated NSCLC
5